Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04299048
Other study ID # C3651009
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 17, 2020
Est. completion date March 30, 2022

Study information

Verified date March 2023
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.


Description:

This 12-week open-label study will explore how PF-06946860 is tolerated, the effects of the study drug, the best dose for treatment and how participants with non-small cell lung, pancreatic or colorectal cancer and cachexia feel after receiving repeated subcutaneous dosing. During the 12-week treatment period, study drug will be administered subcutaneously every 3 weeks for a total of 5 doses. There is a 12-week follow-up period following the last dose of study drug. Additional assessments include: - body weight measurements - blood pressure and heart rate measurements - Lumbar Skeletal Muscle Index (LSMI) by CT scan - Blood samples: - to evaluate safety, - to measure the amount of the study drug in the blood, - to evaluate if the study drug causes an immune response, - to examine the effects of the study drug on levels of a specific cytokine, - and for exploratory samples for bio banking. - Measure the impact of the study drug on appetite, nausea, vomiting, fatigue, physical function, and health-related quality of life with questionnaires. - Measure the impact of study drug on physical activity using wearable digital sensors. - To evaluate the effect of study drug on ability to complete anti-tumor treatment and survival in participants with cancer and cachexia. - To evaluate tumor size.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date March 30, 2022
Est. primary completion date March 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Documented histologic or cytologic diagnosis of advanced metastatic NSCLC, advanced/unresectable pancreatic cancer, or metastatic colorectal cancer. - Cachexia, defined by BMI <20 kg/m2 with involuntary weight loss of >2% within 6 months prior to screening or Involuntary weight loss of >5% within 6 months prior to screening irrespective of BMI or If medical record documentation is unavailable, patient's report will suffice to estimate involuntary body weight loss.; - Will receive the following for non-small cell lung cancer: - a platinum + pemetrexed ± pembrolizumab or - a platinum + nab paclitaxel or paclitaxel ± pembrolizumab or - pembrolizumab alone - Will receive the following for pancreatic cancer: - FOLFIRINOX or - Nab-Paclitaxel + Gemcitabine - Gemcitabine - Will receive the following for colorectal cancer: - FOLFOX +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or - FOLFIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or - FOLFOXIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or - Pembrolizumab for MSI-H • Will be entering the study at the first or second cycle of their current course of anti-cancer treatment/ therapy. - Adequate renal and liver function. - Signed informed consent. Exclusion Criteria: - All other forms of cancers not specified above unless currently considered cured (>5 years without evidence of recurrence). - Planned radiation therapy as part of the primary anti-tumor therapy regimen. However, localized radiation therapy for symptomatic relief is permitted - Cachexia caused by other reasons: Severe COPD requiring use of home O2, heart failure or AIDS. - known symptomatic brain metastases requiring steroids. - Active hepatitis B or C virus. - Confirmed positive HIV test. - Current active reversible causes of decreased food intake. - Receiving tube feedings or parenteral nutrition at Screening. - Elevated blood pressure that cannot be controlled by medications. - Women who are pregnant or breast-feeding

Study Design


Intervention

Drug:
PF-06946860
subcutaneous injection

Locations

Country Name City State
United States American Oncology Partners of Maryland, PA Bethesda Maryland
United States Beverly Hills Cancer Center Beverly Hills California
United States Duke Cancer Center Durham North Carolina
United States Fort Wayne Medical Oncology and Hematology, Inc. Fort Wayne Indiana
United States American Oncology Partners of Maryland, PA Germantown Maryland
United States SCL Health Cancer Centers of Colorado - St. Mary's Hospital and Regional Medical Center Grand Junction Colorado
United States New England Cancer Specialists Scarborough Maine
United States VA Puget Sound Health Care System Seattle Washington
United States Tallahassee Memorial Healthcare Cancer Center Tallahassee Florida
United States Lutheran Medical Center Wheat Ridge Colorado

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With Treatment-Emergent Adverse Events (TEAEs) An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. An AE was considered an TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the last dose plus the lag time were flagged as TEAEs. From Day 1 up to Week 24
Primary Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) Participants with laboratory test abnormalities (without regard to baseline abnormality) that met pre-specified criteria included Hemoglobin< 0.8x lower limit of normal (LLN); Hematocrit< 0.8x LLN; Erythrocytes (Ery.)< 0.8x LLN; Ery. Mean Corpuscular Volume< 0.9x LLN; Leukocytes< 0.6x LLN; Lymphocytes< 0.8x LLN; Bilirubin> 1.5x upper limit of normal (ULN); Aspartate Aminotransferase> 3.0x ULN; Alkaline Phosphatase> 3.0x ULN; Protein< 0.8x LLN; Sodium< 0.95x LLN; Chloride< 0.9x LLN; Calcium< 0.9x LLN; Bicarbonate< 0.9x LLN; Glucose> 1.5x ULN; C Reactive Protein> 1.1x ULN; for urinalysis, Urine Glucose =1, Ketones =1, Urine Protein =1, Urine Hemoglobin =1, Urobilinogen =1, Nitrite =1, and Leukocyte =1 Esterase =1; Hyaline Casts >1/LPF. From Day 1 up to Week 24
Primary Number of Participants With Post-Baseline Vital Signs Abnormalities Vital signs (pulse rate, systolic and diastolic blood pressure) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in vital signs, were supine systolic blood pressure (SBP) <90 millimeters of mercury (mmHg), supine SBP increase/decrease from baseline =30 mmHg; supine diastolic blood pressure (DBP) <50 mmHg, supine DBP increase/decrease from baseline =20 mmHg; supine pulse rate <40 beats per minute (bpm) or >120 bpm. From Day 1 up to Week 24
Primary Number of Participants With Post-Baseline Electrocardiogram (ECG) Abnormalities ECG data (PR interval, QRS interval, QT interval, and QTcF) were obtained with participant in the supine position. The pre-specified categorical analysis criteria in ECG, were PR interval: value =300 milliseconds (msec), percentage change =25/50%; QRS interval: value =140 msec, percentage change =50%; QT interval: value =500 msec; QTcF interval: 470< value =480 msec, 480< value =500 msec, value >500 msec, and 30< change =60 msec, change >60 msec. From Day 1 up to Week 24
Secondary Serum Unbound Trough Concentrations (Ctrough) of PF-06946860 Ctrough was defined as the samples measured pre-dose at Weeks 3, 6, 9 and 12, and at Week 15. Serum unbound Ctrough was summarized by time and treatment group. Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15
Secondary Serum Total Ctrough of PF-06946860 Ctrough was defined as the samples measured pre-dose at Weeks 3, 6, 9 and 12, and at Week 15. Serum total Ctrough was summarized by time and treatment group. Pre-dose at Weeks 3, 6, 9 and 12, and at Week 15
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A